Research on Quality of Life in Female Patients with Congenital Adrenal Hyperplasia and Issues in Developing Nations
Overview
Pediatrics
Affiliations
Congenital adrenal hyperplasia (CAH) is the commonest cause of ambiguous genitalia for female newborns and is one of the conditions under the umbrella term of "Disorders of Sex Development" (DSD). Management of these patients require multidisciplinary collaboration and is challenging because there are many aspects of care, such as the most appropriate timing and extent of feminizing surgery required and attention to psychosexual, psychological, and reproductive issues, which still require attention and reconsideration, even in developed nations. In developing nations, however, additional challenges prevail: poverty, lack of education, lack of easily accessible and affordable medical care, traditional beliefs on intersex, religious, and cultural issues, as well as poor community support. There is a paucity of long-term outcome studies on DSD and CAH to inform on best management to achieve optimal outcome. In a survey conducted on 16 patients with CAH and their parents in a Malaysian tertiary center, 31.3% of patients stated poor knowledge of their condition, and 37.5% did not realize that their medications were required for life. This review on the research done on quality of life (QOL) of female patients with CAH aims: to discuss factors affecting QOL of female patients with CAH, especially in the developing population; to summarize the extant literature on the quality of life outcomes of female patients with CAH; and to offer recommendations to improve QOL outcomes in clinical practice and research.
Psychosocial Development, Sexuality and Quality of Life in Congenital Adrenal Hyperplasia.
Ucar A, Mengen E, Aycan Z J Clin Res Pediatr Endocrinol. 2024; 17(Suppl 1):54-59.
PMID: 39713887 PMC: 11730095. DOI: 10.4274/jcrpe.galenos.2024.2024-6-11-S.
Shafaay E, Aldriweesh M, Aljahdali G, Babiker A, Alomar A, Alharbi K Front Endocrinol (Lausanne). 2023; 14:1122435.
PMID: 37347111 PMC: 10280019. DOI: 10.3389/fendo.2023.1122435.
Waehre A, Heggeli C, Hald K, Myhre A, Diseth T Health Psychol Behav Med. 2022; 10(1):837-854.
PMID: 36105256 PMC: 9467622. DOI: 10.1080/21642850.2022.2116329.
Lasaite L, Navardauskaite R, Semeniene K, Verkauskiene R J Endocrinol Invest. 2022; 45(10):1925-1934.
PMID: 35612812 DOI: 10.1007/s40618-022-01824-4.
Nordenstrom A, Ahmed S, van den Akker E, Blair J, Bonomi M, Brachet C Eur J Endocrinol. 2022; 186(6):G9-G49.
PMID: 35353710 PMC: 9066594. DOI: 10.1530/EJE-22-0073.